Vaccine for Early-Stage Prostate Cancer on Surveillance
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new vaccine (TriAdeno) combined with an immune-boosting drug to help your body fight early-stage prostate cancer while you're on active surveillance—a watchful waiting approach. The vaccine may help prevent cancer growth without surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with early-stage (low or intermediate-risk) prostate cancer confirmed by biopsy
- Currently on active surveillance (not yet treated with surgery, radiation, or hormone therapy)
- Have stored tumor tissue samples from your biopsy (3–24 months old)
- PSA blood level below 20 ng/mL (or below 10 if on certain prostate medications)
- Good organ function shown by blood tests and normal kidney/liver function
- Willing to use birth control during and 1 month after the vaccine series
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
This trial studies a “watchful waiting” approach, where doctors closely monitor certain prostate cancers with regular checkups and repeat biopsies. It may help people avoid or delay treatment side effects while watching for signs the cancer needs treatment.
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
This study follows men with low-risk prostate cancer who choose active surveillance (watching closely instead of immediate treatment). It aims to better track which monitoring results stay reassuring over time, and when treatment might be needed.
This is a registry study that follows men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. It helps doctors understand how safe and effective active surveillance is, including confirming results with repeat biopsies.
Hear when a new Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.